Scientific and Strategic Advisory Board

Dr.Mandar Kulkarni

Dr. Mandar Kulkarni is a Director and Chief Executing Officer at VCR Park, Visakhapatnam.

Dr.Mandar Kulkarni

Dr. Mandar Kulkarni is a Director and Chief Executing Officer at VCR Park, Visakhapatnam. After earning his doctorate in molecular carcinogenesis from Purdue University, he was selected to become a T32 fellow at the Yale School of Medicine and was awarded with a “young scientist award” for his work in the structural biology and signal transduction. As a senior scientist at M/Z Diagnostics, he managed business, obtained an NIH-SBIR grant as a PI, and was awarded with a “young scientist award” by the FSG. At Sandor Lifesciences, as the Head of Molecular Biology and Genomics, he designed and executed numerous NGS, microarray and bioinformatics projects. Then, as the Chief Technology Officer at CGIndia, he managed all operations and lead the development of research services, diagnostics, biopharma services, R&D, and genomics-based clinical assays in the area of precision oncology. He was also responsible for ensuring the financial success of the Indian business unit and established several high value collaborations in the Indian personalized oncology space. Currently, he is also a Vice President, Operations and Management and drives the scientific agenda at Lumiseek.

Dr. Manu Jaggi

Dr. Manu holds a doctorate in Cancer Biology and is a postgraduate in pharmaceutical sciences.

Dr. Manu Jaggi

Dr. Manu holds a doctorate in Cancer Biology and is a postgraduate in pharmaceutical sciences. He has close to 30 years of research experience in drug discovery and preclinical drug development. He did his Ph.D in 1994 from the National Institute of Immunology, New Delhi and joined Dabur in the same year. He holds more than 100 patents and has published over 200 research articles besides writing on current issues in science as a key opinion leader. He has many active collaborations with academic, autonomous and other research organizations and has trained more than 500 biotechnology post-graduate and several Ph.D students. He holds memberships in several scientific committees.

He is the Co-Chair of the Screening Committee of DBT’s NER Twinning R&D Program and a member of Task Force Committee of ICMR besides being on the CII National Committee on Pharma. He is also a member of the Scientific Advisory Committee of CSIR Institutes. He currently leads a team of over 100 scientists engaged in carrying out research in diverse areas such as cancer, chronic inflammation, cardiometabolic disease, skin ailments, cognitive health and diseases of liver and gut. With a sound understanding and experience of global regulatory requirements for IND submission, he has provided key inputs for developing regulatory strategies for preclinical studies to several discovery partners. During last five years, his team has demonstrated the benefits of complementary alternative therapies on strengthening of immunity, anti-aging, reduction of inflammation and improvement of cognitive health.

As Chief Scientific Mentor at Daivam, his current focus is on developing nutraceutical products for wellness and development of biomarkers that have both diagnostic and prognostic value.

Dr. Matt Devalaraja

Dr. Matt Devalaraja is a founder and leads the R&D efforts at Corvidia. Matt is an immunologist

Dr. Matt Devalaraja

Dr. Matt Devalaraja is a founder and leads the R&D efforts at Corvidia. Matt is an immunologist with over 16 years of experience in drug discovery and development across multiple therapeutic areas. Matt was Director of Emerging Innovations Unit at AstraZeneca, where he enabled multiple clinical studies and developed the core hypothesis of precision cardiovascular therapeutics that formed the basis for Corvidia. Prior to that he was Head of Immunology Research, Pharmacokinetics and Toxicology groups at Human Genome Sciences and was integral to the approval of Benlysta for Lupus and Raxibacumab for Anthrax. He started his career at Pfizer Ann Arbor and brought forth the first biologic program for Pfizer’s Global Immunology portfolio. As Head of Biologics Discovery at Pfizer Ann Arbor, he initiated multiple programs across various therapeutic areas including immunology and cardiovascular space, many of which are currently in late stages of clinical development. He is currently on the board of P2D Biosciences and is a founder of multiple startup biotech companies. Matt received his PhD from University of Kentucky and Post-Doctoral training at Vanderbilt University.

Dr. Srinivas R. Kasibhatla

Dr. Srinivas R. Kasibhatla has over 25 years of drug discovery experience in multinational pharmaceuticals and small biotech companies across multiple therapeutic areas.

Dr. Srinivas R. Kasibhatla

Dr. Srinivas R. Kasibhatla has over 25 years of drug discovery experience in multinational pharmaceuticals and small biotech companies across multiple therapeutic areas that include cancer, diabetes, obesity, Neuroscience, immunology, cardiovascular and infectious diseases. He has contributed to the discovery of 11 clinical candidates - cancer (4), diabetes (2), immunology (1), Neuroscience (1) and cardiovascular (2). He was the lead inventor or co-inventor on several issued and published patents.

He is Currently the founder and CEO of Innovative Discovery Partners at San Diego, started by him in 2018, where he is a Pharmaceutical consultant working in the areas of medicinal chemistry, drug discovery project management, and intellectual property. Earlier he worked at Beta Cat Pharmaceuticals, Houston, as Vice President Chemistry, Xetrios Therapeutics, San Diego, as Vice President Chemistry, BMS Biocon Research Center (BBRC), Bangalore, as Head Discovery Chemistry, Jubilant Biosys, Bangalore as Vice President Discovery Chemistry, IOGEN IDEC, San Diego, as Head of Med Chem, Conforma Therapeutics, San Diego as Director Medicinal Chemistry, Metabasis Therapeutics Inc., (Formerly Gensia), San Diego, as Senior Scientific Investigator.

He did his Master of Science and Doctoral Research from University of Hyderabad and Post-Doctoral Training at Harvard University. He has 29 patents and 35 publications for his credit.

Dr. Muthu Dhandapani

Dr. Muthu Dhandapani, is a regulatory and product development expert, seasoned professional with 18 years of experience in matrix management

Dr. Muthu Dhandapani

Dr. Muthu Dhandapani, is a regulatory and product development expert, seasoned professional with 18 years of experience in matrix management; collaborating with production, HR, Finance, Supply Chain, Legal, Operations, QA, and RA to ensure smooth and efficient, daily functions across the organization. He is a certified professional in Lean Six Sigma, GLP, GMP, ICH-GCP. IRCA-CQI Certified Medical Device Professional (CMDP) and certified Lead Auditor for ISO 13485:2016 with MDSAP. In addition, he also has expertise in in-vitro diagnostics, cellular therapeutics, biologics, regenerative medicine/tissue engineering based products, Class III medical devices like surgical dressings, hemostats, bone fills, dental fills, and scar management products. His most notable experiences and achievements include 2 technology transfers using transformational leadership style, and served as consultants to 10 med-tech startups. He has authored international peer reviewed publications with 371 Google Scholar citations and one patent. He is also a recipient of Indian Achievers Award 2018 & Bharat Vikas Award 2019.

Dr. Anitha Reddi

Dr. Anitha Reddi is an expert in both clinical and non-clinical operations. Dr Anitha has 20 years of experience as a non-practicing physician,

Dr. Anitha Reddi

Dr. Anitha Reddi is an expert in both clinical and non-clinical operations. Dr Anitha has 20 years of experience as a non-practicing physician,and as a versatile Director/Practice Manager, specializing in clinical research, site-specific protocol development, and financial management for study budgets. She has extensive expertise overseeing clinical and non-clinical operations for Medical Oncology and wellness programs. Her most notable accomplishments include directing and implementing the oncology service line, optimizing workflow efficiency, and fostering collaborative relationships with healthcare professionals.

She has a proven track record of successfully launching new clients, establishing partnerships with medical oncologists, and implementing Electronic Medical Record systems to ensure exceptional patient care and regulatory compliance. Her strong background in strategic planning and budgeting has been instrumental in driving program growth. Additionally, she has played a key role in restructuring wellness programs and executing impactful marketing initiatives.